Oruka Therapeutics Inc

Aruka Therapeutics insider activity shows finance leader’s disciplined buys and sales under a Rule 10b5‑1 plan, signaling confidence amid biotech regulatory shifts.

Oruka Therapeutics insider buys reveal confidence amid capital strain: CMO’s 18% stake jump, market sentiment, and future milestones.

Oruka Therapeutics insider moves: COO buys low, sells via Rule 10b5‑1, showing confidence amid price swings and heart‑failure pipeline prospects.

Oruka insider buys 7,000 shares at $6.84‑$7.80 while selling higher‑priced shares, signaling confidence ahead of Phase‑1 data that could lift its negative‑P/E biotech into growth mode.